GSK/Tesaro claim denied in Jemperli lawsuit with AnaptysBio
A court ruling in the US has delivered a setback for GSK and its Tesaro subsidiary in their dispute with AnaptysBio over cancer drug Jemperli.
Newsletters and Deep Dive digital magazine
A court ruling in the US has delivered a setback for GSK and its Tesaro subsidiary in their dispute with AnaptysBio over cancer drug Jemperli.
Sky-high expectations for sales of Eli Lilly's new oral GLP-1 agonist Foundayo have been dented by preliminary sales data from IQVIA.
After downplaying persistent rumours for months, Sun Pharma has broken cover with an $11.75 billion takeover agreement for Organon.
March saw a handful of noteworthy hires in the agency, consultancy, and investor spaces.
AbbVie's bid to bring a rapid and shorter-acting botulinum toxin product to the US market has been knocked back by the FDA.
Editor's Picks
Newsletters and Deep Dive
digital magazine